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The ongoing global pandemic caused by the severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2), the agent of novel coronavirus disease 2019 (COVID-19), has resulted in over 1 
million deaths worldwide and many more cases of respiratory failure.1  The propensity of SARS-
CoV-2 to cause catastrophic pneumonia fulfilling criteria for the acute respiratory distress 
syndrome (ARDS) has not only strained the capacity of intensive care units (ICU) to provide 
mechanical ventilation but has also led to a spike in utilization of veno-venous (V-V) 
extracorporeal membrane oxygenation (ECMO) for respiratory failure not seen since the H1N1 
influenza pandemic.2  The explosion in the use of extracorporeal support is likely to magnify 
unresolved controversies surrounding the management of patients receiving ECMO.  One such 
controversy is whether administration of prophylactic antifungal therapy reduces the incidence of 
Candida bloodstream infection (C-BSI) associated with vascular cannulation.   
The concern about C-BSI in the setting of ECMO is not trivial. Together with gram negative 
bacilli and enterococci, Candida spp are among the three most common pathogens implicated in 
central venous catheter-related BSI (CVC-BSI) in critically ill patients.3  The impact of COVID-
19 on the contribution of Candida to CVC-BSI in intensive care units remains to be elucidated, 
though such infections have likely increased during the pandemic.4  Although there are 
conflicting data on whether ECMO cannulation confers greater risk of CVC-BSI than 
conventional catheterization,5,6 routine antibacterial prophylaxis of ECMO patients was reported 
by 42% of participating centers in the Extracorporeal Life Support Organization (ELSO) in a 
2011 study.7  Routine antifungal prophylaxis, on the other hand, was reported by a mere 2% of 
programs that year.  By 2017, however, 47% of international respondents reported the use of 
antifungal prophylaxis.8  An impromptu survey of the authorship of this Brief Communication, 







and therapeutics10, revealed that antifungal prophylaxis of ECMO recipients is currently a 
common practice in the represented institutions.  Given the possibility that this may be a growing 
phenomenon in the management of the ECMO patient, the consensus among the author group is 
that routine antifungal prophylaxis of the immunocompetent adult patient receiving V-V ECMO 
for acute respiratory failure can only be judged in the context of available indirect evidence as it 
has never been studied directly. 
A subset of ECMO patients, namely pediatric cardiac veno-arterial (V-A) ECMO recipients11 
and adults on V-A ECMO following orthotopic heart transplantation12 appear to be at especially 
high risk for C-BSI.  Recognizing this, the ELSO Infectious Disease Task Force advocates for 
“cautious but aggressive” use of antifungal prophylaxis in patients deemed to be at particularly 
high risk, including those with compromised immunity.13  Of note, the only study to have 
assessed the impact of antifungal prophylaxis (with fluconazole) in ECMO patients was 
performed in the pediatric cardiac V-A ECMO population and showed a non-significant 
reduction in the incidence of fungemia with prophylaxis (2.4%) compared to the already low 
incidence in the no-prophylaxis group (4.5%).11 In an unselected adult population of ECMO 
recipients, the prevalence of candidemia is remarkably low: 1.2% in a study of 19,697 such 
patients from the ELSO registry.14  Even Candida colonization rates of ECMO cannulas have 
been found to range from 0 to only 10%, and when present, Candida colonization is less 
common than Gram positive and Gram negative bacterial colonization.15,16  Although in 
aggregate bacterial isolates exceed fungal ones in ECMO patients with BSI, there has been no 








In evaluating the justification for routine antifungal prophylaxis of immunocompetent adult V-V 
ECMO recipients, it is helpful to draw on existing prophylaxis data in immunocompetent 
critically ill non-ECMO populations.  In the seminal prospective surgical ICU study by Pelz et 
al, fluconazole prophylaxis significantly reduced the incidence of IC from 15.4% in the placebo 
arm to 8.5% in the intervention arm.19  When added to a selective digestive decontamination 
regimen in a mixed ICU population, fluconazole likewise significantly reduced IC incidence 
from 16% with placebo to 5.8% with active prophylaxis.20   Despite a comparable sample size to 
these earlier studies, a significant reduction was not achieved in a subsequent trial of caspofungin 
prophylaxis limited to medical ICU patients in whom the incidence of IC in the placebo group 
was only 4.8%.21  Although much lower than expected by the study authors, the 4.8% incidence 
was actually higher than the 3.1% incidence of candidemia registered in a prospective cohort of 
1,655 non-neutropenic mixed ICU patients.22  Returning to the question of antifungal 
prophylaxis during immunocompetent adult V-V ECMO use, when the cumulative incidence of 
C-BSI in such cases is calculated from the major available studies reporting this metric, a figure 
of 4.2% is obtained (Table 1).  This is of relevance because aforementioned studies of critically 
ill populations in which the baseline incidence of candidemia or IC was in the range of 4.2-4.8% 
have not shown benefit of antifungal prophylaxis. 
Extrapolation of the above IC incidence analysis to V-V ECMO in COVID-19 pneumonia is 
potentially confounded by, among other factors, the frequent provision of immunomodulatory 
therapy for this disease.27,28  Nonetheless, if the incidence of C-BSI in V-V ECMO patients is 
accepted to be under 5% as suggested by aggregate data, we submit that universal antifungal 
prophylaxis cannot be supported at the present time assuming adherence to recommended circuit 







C-BSI rates.  Although generally well tolerated, widespread administration of antifungal agents 
for prolonged periods raises concerns about cost, toxicity, and selection for resistant isolates.  
With the ongoing SARS-CoV-2 pandemic showing no signs of abating, the current “boom” in V-
V ECMO use is expected to continue as ICUs across the globe admit patients with catastrophic 
respiratory failure on an unprecedented scale.  The transition of ECMO from an exceptional 
management strategy in normal times to a widely adopted rescue maneuver during a respiratory 
virus outbreak magnifies the importance of associated decisions such as antifungal prophylaxis.  
Previously an overlooked issue in intensive care medicine, antifungal prophylaxis in the ECMO 
recipient now merits greater attention.  While challenging in many ways, current pandemic 
conditions may paradoxically offer a singular window of opportunity to prospectively investigate 
the impact of antifungal prophylaxis on C-BSI in adult patients with respiratory failure 
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Table 1.  Summation of 5 available studies,16,23-26 all retrospective, of immunocompetent adult 
ECMO recipients from which the incidence of blood stream infection caused by Candida spp (C-
BSI) could be derived specifically for those connected to veno-venous (V-V) support.*  Included 
studies were either exclusively of V-V ECMO or of both V-V and veno-arterial (i.e., mixed) but 
from which the incidence in the V-V population could be determined separately.  The incidence 
of C-BSI as a proportion of all BSI is also provided.   
Study/Year V-V or Mixed N (Patients) Incidence C-BSI (%)  C-BSI fraction of BSI (%) 
Pieri 201323 Mixed 22 2/22 (9.1%) 2/4 (50%) 
Austin 201724 Mixed 34 0/34 (0%) 0/1 (0%) 
Kutleša 201725 V-V 100 1/100 (1%) 1/35 (2.9%) 
Thomas 201716 V-V 103 8/103 (7.8%) 8/43 (18%) 
Na 201826 V-V 121 5/121 (4.1%) 5/21 (23.8%) 
Totals 2 Mixed, 3 V-V 380 16/380 (4.2%) 16/104 (15.4%) 
     *Eligible studies were obtained through a PubMed search up to the current date using the 
terms “extracorporeal membrane oxygenation AND fungal” as well as “extracorporeal 
membrane oxygenation AND Candida.”  Search results selected for full-text review were limited 
to those in the English language and those of adult patients.  Information needed to populate the 
table was abstracted from the relevant studies thus identified.                        
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